SCHEMBL4277944

SCHEMBL4277944

O=S(=O)(c1ccccc1)N(C1CC1)C1CCN(Cc2ccc(OCc3ccccc3)cc2)CC1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.60
RAB9A P51151 3/20 0.60
TP53 P04637 3/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
KDM4E B2RXH2 2/20 0.53
MEN1 O00255 1/20 0.53
ALDH1A1 P00352 1/20 0.53
KMT2A Q03164 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
HRH3 Q9Y5N1 3/20 0.53
MMP1 P03956 1/20 0.50
MMP9 P14780 1/20 0.50
MMP13 P45452 1/20 0.50
ADAM17 P78536 1/20 0.50
SLC6A5 Q9Y345 1/20 0.50
CHRM4 P08173 1/20 0.50
S1PR5 Q9H228 1/20 0.50
LMNA P02545 1/20 0.49
OPRL1 P41146 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14997384 0.88 HTR2A (0.61) SMN1; SMN2CHRM4
SCHEMBL4285152 0.86 SIGMAR1 (0.56) KDM4EMEN1ALDH1A1KMT2AMMP1
SCHEMBL4285276 0.83 CHRM4 (0.56) HRH3CHRM4
SCHEMBL4282387 0.81 ALDH1A1 (0.51) KDM4EALDH1A1
SCHEMBL4277843 0.81 ACHE (0.55) SMN1; SMN2KDM4EMEN1ALDH1A1KMT2A
SCHEMBL4284277 0.80 HTR2A (0.48) SMN1; SMN2ALDH1A1LMNA
SCHEMBL4286138 0.80 MEN1 (0.50) MEN1KMT2ALMNA
SCHEMBL7213083 0.79 NPC1 (0.53) NPC1RAB9ATP53SMN1; SMN2KDM4E
SCHEMBL13541677 0.77 CACNA1B (0.53) ALDH1A1
SCHEMBL1143656 0.76 NPC1 (0.85) NPC1RAB9ATP53SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9000174-B2 4-phenylsulfonamidopiperidines as calcium channel blockers PURDUE PHARMA L.P. (US) 2015-04-07 US disclosed
EP-1814851-B1 4-PHENYLSULFONAMIDOPIPERIDINES AS CALCIUM CHANNEL BLOCKERS EURO CELTIQUE SA (LU) 2013-06-05 EP disclosed
US-20090105249-A1 4-phenylsulfonamidopiperidines as calcium channel blockers EURO-CELTIQUE S.A. (LU) 2009-04-23 US disclosed
CN-101044116-A 4-phenylsulfonamidopiperidines as calcium channel blockers EURO CELTIQUE SA (LU) 2007-09-26 CN disclosed
EP-1814851-A2 4-PHENYLSULFONAMIDOPIPERIDINES AS CALCIUM CHANNEL BLOCKERS EURO-CELTIQUE S.A. (LU) 2007-08-08 EP disclosed
WO-2006040181-A2 4-PHENYLSULFONAMIDOPIPERIDINES AS CALCIUM CHANNEL BLOCKERS EURO-CELTIQUE S.A. (LU) 2006-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105249-A1 4-phenylsulfonamidopiperidines as calcium channel blockers CACNA1A, CACNA1E, CACNA1B NPC1 710/4885RAB9A 1587/4885TP53 3848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.